002437 誉衡药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)6.67417.76012.8867.308-16.527
总资产报酬率 ROA (%)4.97112.6487.7883.330-6.644
投入资产回报率 ROIC (%)6.30216.91210.5484.311-8.525

边际利润分析
销售毛利率 (%)46.35945.34753.46058.38956.925
营业利润率 (%)18.22418.96111.6716.666-8.690
息税前利润/营业总收入 (%)18.37319.16611.5797.924-7.173
净利润/营业总收入 (%)16.12017.9059.9374.901-9.315

收益指标分析
经营活动净收益/利润总额(%)83.38355.96778.23277.354-22.987
价值变动净收益/利润总额(%)2.78734.789-3.077-23.40499.959
营业外收支净额/利润总额(%)-0.0771.149-0.4090.979-0.151

偿债能力分析
流动比率 (X)1.8841.6531.0660.8180.777
速动比率 (X)1.6271.3950.8370.6830.686
资产负债率 (%)23.66426.31930.16745.74958.187
带息债务/全部投入资本 (%)4.0055.0731.62029.48547.661
股东权益/带息债务 (%)2,372.2281,849.4295,981.618234.766107.551
股东权益/负债合计 (%)320.086278.020228.885115.22368.810
利息保障倍数 (X)112.688-1,201.936-264.7006.646-4.769

营运能力分析
应收账款周转天数 (天)22.06021.19924.34629.73726.273
存货周转天数 (天)66.19060.85160.11166.68276.131